Ravindran Lakshmi N, Stein Murray B
Department of Psychiatry, University of California San Diego, 8939 Villa La Jolla Drive, Suite 200, La Jolla, CA 92037, USA.
Curr Top Behav Neurosci. 2010;2:505-25. doi: 10.1007/7854_2009_15.
Post-traumatic stress disorder (PTSD) is a prevalent psychiatric disorder that may result in significant social and occupational debilitation unless symptoms are recognized and treated appropriately. Considerable research effort has been devoted over the last 20 years to developing effective pharmacological treatments for this illness. At this time, the bulk of the agents investigated include antidepressants, anticonvulsants, atypical antipsychotics, benzodiazepines, and antiadrenergic agents. Herein, we review the existing evidence base for these different classes of psychotropics in PTSD. Emphasis is placed on discussion of evidence stemming from randomized placebo-controlled clinical trials wherever possible. A brief description of novel agents that have shown initial promise for PTSD treatment is also provided.
创伤后应激障碍(PTSD)是一种常见的精神障碍,若症状未得到识别和恰当治疗,可能导致严重的社交和职业功能衰退。在过去20年里,人们投入了大量研究精力来开发针对这种疾病的有效药物治疗方法。目前,所研究的大部分药物包括抗抑郁药、抗惊厥药、非典型抗精神病药、苯二氮䓬类药物和抗肾上腺素能药物。在此,我们回顾了PTSD中这些不同类别的精神药物的现有证据基础。只要有可能,重点将放在对随机安慰剂对照临床试验证据的讨论上。还简要介绍了对PTSD治疗已显示出初步前景的新型药物。